NCT06984328View on ClinicalTrials.gov

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

July 15, 2027

Study Completion Date

July 15, 2029

Conditions
Cutaneous MelanomaRelapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)Metastatic Cutaneous Melanoma (Stage IV)
Interventions
BIOLOGICAL

Acasunlimab

Intravenous (IV) infusion

BIOLOGICAL

Pembrolizumab

IV infusion

Trial Locations (2)

37203

RECRUITING

Tennessee Oncology, PLLC, Nashville

00909

RECRUITING

Pan American Center for Oncology Trials, LLC, San Juan

Sponsors

Lead Sponsor

Genmab
All Listed Sponsors
lead

Genmab

INDUSTRY